HeartCare Articles. Save. Your. Heart.

Eisai Subsidiary Launches Research Operations In Kobe

April 23, 2017

KAN Research Institute, Eisai's research subsidiary, has begun research operations in its new facilities in the Kobe Medical Industry Development Project site.

KAN aims to discover innovative ideas and technology that lead to new pharmaceutical development, focusing on cellomics in order to explore how cells interact with each other and orchestrate to shape vital activities of a human body.

KAN will mainly target neurology areas such as Alzheimer's disease and Parkinson's disease, oncology areas such as malignant tumor, metastasis and vascularization, and immunology and inflammation areas including rheumatoid arthritis and inflammatory bowel disease.

The research is expected to produce outcome for use in translational research from basic study for drug discovery, which will likely contribute to the R&D activities of Eisai worldwide.

The reinforced facilities will allow KAN to take advantage of the bio cluster district on the site to accelerate research through the extended network of researchers who work there.

By Aiko Seymour, JCN Staff Writer

Copyright 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK

JCN